Implementing EjtM₃ (European Journal of Translational Myology, Mobility, Medicine) along the silk-road

Paola Arslan, Barbara Ravara

Interdepartmental Research Center of Myology, Department of Biomedical Sciences, University of Padova, Padova, Italy E-mail: barbara.ravara@unipd.it

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Two main novelties will appear in the second 2018 Issue of the European Journal of Translational Myology demonstrating that the journal is vital and in expansion, one novelty is that the journal is implementing its authorship and readership to broader clinical fields from muscle myology and mobility to clinical medicine and surgery. Consequently, the Editorial Board is also expanding to allow a broader expert evaluation of Authors submitted typescripts. The expanded Editorial Board recently evaluated the option to change the name of the journal from EjtM to EjtM3 (Myology, Mobility, Medicine), in order to expand the original journal title meaning. Another important novelty is the first BAM Seminal Paper by Damrauer et al. 18 (5): 139-148, 2008. It is now reprinted (with Basic and Applied Myology permission) in this EjtM 28 (2), 2018. The topic (chemotherapy-induced muscle wasting) was up-dated by one of our Editors stressing the relevance of the BAM 2008 paper to focus attention not only of myologists, but also of oncologists. From 2008, BAM (renamed from 2010 European Journal of Translational Myology) went far beyond the limits of pure Myology. Al last, but hopefully not at least, a series of Rapid Reports from Iranian Authors are paving the pathway Venetia–extreme Orient, along the ancient silk-road. EjtM will enthusiastically publish clinical activities from surrounding and extreme Orient. The Marco Polo tradition and his bravery seem successfully continuing.

Key Words: EjtM, EjtM3, translational myology, mobility, medicine, rapid report

The issue 28 (2), 2018 of the European Journal of Translational Myology (EJTM) is implementing two main novelties, that are demonstrating that the journal is vital and expanding its authorship and readership to broader clinical fields from mobility to general medicine and surgery. mobility to clinical medicine and surgery. Consequently, the Editorial Board is also expanding to allow a broader expert evaluation of Authors submitted typescripts. The expanded Editorial Board recently evaluated the option to change the name of the journal from EjtM to EjtM3 (Myology, Mobility, Medicine), in order to expand the original journal title meaning. We are not considering this option, i.e., to move the name of the journal from EjtM to EjtM3 (Myology, Mobility, Medicine),¹ but to extend its interests and authorships. Another important novelty is the first BAM Seminal Paper by Damrauer et al. (reprinted with permission from Basic Applied Myology 18 (5): 139-148, 2008).² A review of one of our Editors up-date the topic (chemotherapy-induced muscle wasting) and stress the relevance of the BAM 2008 paper to focus attention not only of myologists, but also of oncologists.³ After the interesting original article of Renzini et a.,⁴ that describes the culture conditions able to positively influence satellite cell activation and survival of single myofibers in vitro. At last, but hopefully not at least, a series of Rapid Reports from Iranian Authors are paving the pathway Venetia–extreme Orient, along the ancient silk-road.⁵ Indeed, in the previous 28 (2), 2018 EJTM Issue dedicated to the Giovanni Salvati Memorial,¹⁴ Iranian authors also published a few papers,¹⁵-¹⁸ that opened the way for submissions beyond the topic of Mobility to a broader series of medical and surgical researches and trials. The Advisors are, thus, inviting potential Authors of the incoming EJTM Issues to submit typescripts taking into account that the journal is keen to publish high level papers in the fields of Myology, Mobility and Medicine. The Marco Polo tradition and his bravery seem successfully continuing.

Acknowledgments

BR thanks for support the A&C M-C Foundation for Translational Myology, Padova, Italy.

Funding: This typescript is supported by the A&C M-C Foundation for Translational Myology, Padova, Italy.

Conflict of Interest

The authors declare to have none conflict of interests.

Ethical Publication Statement

Author confirms that he has read the Journal’s position on issues involved in ethical publication and affirms that this report is consistent with those guidelines.
Corresponding Author
Barbara Ravara, Interdepartmental Research Center of Myology, Department of Biomedical Sciences, University of Padova, Via Ugo Bassi 59/B, I-35131 Padova, Italy. E-mail: barbara.ravara@unipd.it

Email of coauthor
Paola Arslan: paola.arslan@unipd.it

References

Received for publication: June 12, 2018
Accepted for publication: June 14, 2018